000520.KS
Samil Pharmaceutical Co.,Ltd
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 6,080.00
−0.82%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 207.4B | 210.4B | 219.7B | 196.3B | 179.7B |
| Cost of Revenue | 140.7B | 142.8B | 138.8B | 124.1B | 112.2B |
| Gross Profit | 66.7B | 67.4B | 80.9B | 72.2B | 67.5B |
| Operating Expenses | |||||
| R&D Expense | 6.4B | 8.5B | 6.4B | 5.6B | 2.9B |
| SG&A Expense | 55.5B | 42.1B | 35.5B | 60.0B | 29.2B |
| General & Admin Expense | 20.2B | 23.5B | 17.7B | 14.7B | 10.4B |
| Selling & Marketing Expense | 18.4B | 18.6B | 17.8B | 16.6B | 18.8B |
| Other Expenses | 36.8B | 40.8B | 38.8B | 188.7M | 31.4B |
| Total Operating Expenses | 96.8B | 91.4B | 80.8B | 65.8B | 63.5B |
| Cost and Expenses | 237.5B | 234.2B | 219.6B | 189.9B | 175.7B |
| Operating Income (EBIT) | (30.1B) | (23.9B) | 113.0M | 6.5B | 4.0B |
| Non-Operating | |||||
| Interest Income | 44.8M | 49.0M | 61.1M | 33.4M | 68.1M |
| Interest Expense | 8.8B | 8.8B | 5.1B | 3.5B | 4.3B |
| Net Interest Income | (8.8B) | (8.7B) | (5.0B) | (3.5B) | (4.2B) |
| Other Non-Op Income/Expense | (9.4B) | (13.2B) | (3.7B) | (5.0B) | (3.0B) |
| Non-Operating Income (excl Interest) | 2.3B | 6.2B | (1.3B) | 1.5B | (1.3B) |
| EBT (Pre-Tax Income) | (39.6B) | (37.2B) | (3.6B) | 1.4B | 1.1B |
| Income Tax Expense | (2.0B) | (2.5B) | 2.0B | (239.8M) | 1.1B |
| Bottom Line | |||||
| Net Income | (37.5B) | (34.6B) | (5.6B) | 1.7B | (28.3M) |
| Earnings from Cont. Ops | (37.5B) | (34.6B) | (5.6B) | 1.7B | (28.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (37.5B) | (34.6B) | (5.6B) | 1.7B | (28.3M) |
| Per Share | |||||
| Basic EPS | (₩1,764) | (₩1,628) | (₩313) | ₩116 | (₩2) |
| Diluted EPS | (₩1,764) | (₩1,628) | (₩313) | ₩115 | (₩2) |
| Revenue Per Share | ₩9,707 | ₩9,901 | ₩12,217 | ₩13,709 | ₩12,912 |
| Shares | |||||
| Basic Shares Outstanding | 21.4M | 21.2M | 18.0M | 14.3M | 13.9M |
| Diluted Shares Outstanding | 21.4M | 21.2M | 18.0M | 14.4M | 13.9M |
| Profitability Metrics | |||||
| EBITDA | (39.4B) | (10.7B) | 8.7B | 10.3B | 10.3B |
| D&A | 13.7B | 13.2B | 7.2B | 5.4B | 5.0B |
| EBIT | (30.4B) | (23.9B) | 1.4B | 5.0B | 5.3B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026